ER, PR, CERB-B2, KI-67, P53, BCL-2, CYCLIN-D1 EXPRESSIONS IN INVASIVE BREAST CARCINOMAS AND COMPARISON WITH THE CLINICAL AND HISTOPATHOLOGICAL PARAMETERS
DOI:
https://doi.org/10.53555/nnmhs.v4i9.606Keywords:
Breast carcinoma, ER, PR, cerb-B2, ki-67, p53, Bcl-2, Cyclin-D1Abstract
Aim:The aim of this study was to evaluate ER(Estrogen-receptor), PR(Progesteronreceptor), cerb-B2, ki-67, p53, Bcl2(B cell lymphoma-2), Cyclin-D1 expressions in invasive breast carcinomas and compare them with the clinical and histopathological parameters.
Methods: We analyzed 70 female patients retrospectively who underwent Modified Radical Mastectomy with Axillary lymph node dissection and were diagnosed as Invasive ductal carcinoma of the breast-Not otherwise specified at Muğla
Sıtkı Koçman University, Faculty of Medicine, Department of Pathology between 2012 and 2016.
ER, PR, cerb-B2, ki-67, p53, Bcl-2, Cyclin-D1 expressions of these tumors were obtained by immunohistochemistry. Clinical parameters of the patients were obtained from the hospital automation system.
Results: Bcl-2; was found to be more positive in patients with young age, small and lowgrade, ER/ PR-positive tumors without distant organ metastasis. However, Bcl-2 negativity was found to be higher in p53, cerb-B2 positive and fastlygrowing (tumors with high ki67 index) tumors.
Cyclin-D1; was found to be more positive in small and low-grade, slowly-growing (tumors with low ki-67 index), cerbB2 and p53 negative tumors without vascular invasion and axillary lymph node metastasis.
Conclusion: These results were interpreted as; Bcl-2 and Cyclin-D1 positivity were in favor of better outcome and better prognosis.
References
Colditz G, Chia KS. Invasive breast carcinoma. In: WHO Classification of tumours of the breast. 4th ed. Lyon, IARCH;2012. p. 14-38.
Elesawy BH, El-hafez AA, Shawky AE, Arafa M. Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: A clinicopathologic study on 123 patients. Ann Diagn Pathol 2014;18:21-6.
Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY. Expression of cerb-B2, Cyclin-D1 and Estrogen Receptor and their clinical implications in the Invasive Ductal Carcinoma of the breast. Jpn J Clin Oncol 2007;37(9):708-14.
Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesteron receptor and HER2 in breast cancer. Mod Pathol 2010;23(2):52-9.
Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype . Cancer Biol Med 2016;13(4):496-504.
Abubakar M, Orr N, Daley F, et al. Prognostic value of automated Ki-67 scorring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res 2016;18:104. DOI: 10.1186/s13058-016-0765-
Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triplenegative breast cancer patients. PLoS ONE 2017;12(2):e0172324.
Yang P, Du CW, Kwan M, Liang SX, Zhang GJ. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Scientific Reports 2013;3:2246. DOI: 10.1038/srep02246.
Seong MK, Lee JY, Byeon J, et al. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Breast Cancer Res Treat 2015;150:141-8.
Dawson SJ, Makretsov N, Blows FM, et al. Bcl-2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy. Br J Cancer 2010;103:668–75.
Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index. Clin Cancer Res 2006;12:2468– 75.
Eramah E, Buhmeida A, Khaled BR, et al. Prognostic value of Bcl-2 expression among women with breast cancer in Libya. Tumor Biol 2013;34:1569-78.
Yu B, Sun X, Shen HY, Gao F, Fan YM, Sun ZJ. Expression of the apoptosis-related genes Bcl-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res 2010;29:1–
Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat 2009;115:343–8.
Mylona E, Tzelepis K, Theohari I, Giannopoulou I, Papadimitriou C, Nakopoulou L. Cyclin-D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathol 2013;62:472-80.
Peurala E, Koivunen P, Haapasaari KM, Bloigu R, Jukkola-Vuorinen A. The prognostic significance and value of Cyclin-D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013, 15/1:R5:1-10.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer.The value of histological grade in breast cancer; experience from a large stugy with long term followup. Histopathol 1998;19:403-10.
Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-24.
Solin LJ, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS Score from ECOG E5194. Cancer Res 2011;71:108S.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Tresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary theraphy of early breast cancer. Ann Oncol 2009;20:131929.
Cabioglu N, Ozman V, Kaya H, et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 2009;208:67-74.
Wu SG, Li H, Tang LY, et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. Tumour Biol 2017 Jun;39(6):1010428317705082.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 Jun 1;28(16):2784-95.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun;134(6):907-22.
Epstein M, Ma Y, Press MF. Erb-B2 testing: assessment of status for targetted therapies. In: Diseases of the breast, 4th ed. Philadelphia: Wolters Kluwer Lippincott Williams&Wilkins; 2010. P. 431-42.
Wolff AC, Hammond ME, Hicks DG, et al. American Society of Clinical Oncology; College of American
Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American
Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
Juan Rosai. Breast.Rosai and Ackerman’s Surgical Pathology. Elsevier,10th ed 2011
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
